Myelodysplastic syndromes (alone or in combo with hypomethylating agents) | KCP-8602-801

Indications: Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration Resistant Prostate Cancer (mCRPC) ,Higher Risk Myelodysplastic Syndrome (HR-MDS)
Drug: Eltanexor

Please visit clinicaltrials.gov for more information about this study

This trial is for eltanexor.

Phase 1Phase 2Phase 3Commercial
Phase 1
Phase 2
Phase 3
Commercial